Aerovate Therapeutics Inc Gross Working Capital is USD 87.28 M for the quarter ending March 31, 2024, a -20.34% change year over year. Gross working capital is a financial metric that represents the amount of a company's current assets available to cover its current liabilities and short-term debt obligations. It is calculated by subtracting the sum of current liabilities and short-term debt from the total current assets of a company. Gross working capital provides insights into a company's short-term liquidity and its ability to meet its financial obligations in the near future.